JP2019519533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519533A5 JP2019519533A5 JP2018561938A JP2018561938A JP2019519533A5 JP 2019519533 A5 JP2019519533 A5 JP 2019519533A5 JP 2018561938 A JP2018561938 A JP 2018561938A JP 2018561938 A JP2018561938 A JP 2018561938A JP 2019519533 A5 JP2019519533 A5 JP 2019519533A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- yap
- subject
- gls1
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 62
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 18
- 102100025960 Glutaminase kidney isoform, mitochondrial Human genes 0.000 claims description 17
- 101000856990 Homo sapiens Glutaminase kidney isoform, mitochondrial Proteins 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims description 14
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims description 8
- 229960003895 verteporfin Drugs 0.000 claims description 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- KLQLQDLJJUAEGT-ZBFHGGJFSA-N CO[C@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC=CC=1)C1=CC=CC=C1 Chemical compound CO[C@H](C(=O)NC=1SC(=NN=1)N[C@H]1CN(CC1)C=1N=NC=CC=1)C1=CC=CC=C1 KLQLQDLJJUAEGT-ZBFHGGJFSA-N 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022079875A JP7411967B2 (ja) | 2016-05-26 | 2022-05-16 | 肺血管疾患を治療するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341848P | 2016-05-26 | 2016-05-26 | |
| US62/341,848 | 2016-05-26 | ||
| PCT/US2017/034420 WO2017205595A1 (en) | 2016-05-26 | 2017-05-25 | Compositions and methods for treating pulmonary vascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079875A Division JP7411967B2 (ja) | 2016-05-26 | 2022-05-16 | 肺血管疾患を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519533A JP2019519533A (ja) | 2019-07-11 |
| JP2019519533A5 true JP2019519533A5 (OSRAM) | 2020-06-25 |
| JP7079937B2 JP7079937B2 (ja) | 2022-06-03 |
Family
ID=60412630
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561938A Active JP7079937B2 (ja) | 2016-05-26 | 2017-05-25 | 肺血管疾患を治療するための組成物および方法 |
| JP2022079875A Active JP7411967B2 (ja) | 2016-05-26 | 2022-05-16 | 肺血管疾患を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022079875A Active JP7411967B2 (ja) | 2016-05-26 | 2022-05-16 | 肺血管疾患を治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10925869B2 (OSRAM) |
| EP (2) | EP3463574B1 (OSRAM) |
| JP (2) | JP7079937B2 (OSRAM) |
| KR (2) | KR20220120711A (OSRAM) |
| CN (2) | CN109843378B (OSRAM) |
| AU (1) | AU2017270092B2 (OSRAM) |
| WO (1) | WO2017205595A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10925869B2 (en) | 2016-05-26 | 2021-02-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for treating pulmonary vascular disease |
| EP3713569B1 (en) * | 2017-11-22 | 2024-03-13 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease |
| JP7156856B2 (ja) * | 2018-08-21 | 2022-10-19 | 国立大学法人富山大学 | 抗肥満剤 |
| EP3690110B1 (en) | 2019-02-01 | 2021-06-02 | LG Electronics Inc. | Laundry treating apparatus |
| EP3690108B1 (en) | 2019-02-01 | 2021-05-12 | LG Electronics Inc. | Laundry treating apparatus |
| EP3690109B1 (en) | 2019-02-01 | 2021-05-05 | LG Electronics Inc. | Laundry treating apparatus |
| US20220233535A1 (en) * | 2019-05-05 | 2022-07-28 | Georgetown University | Use of inhibitors of yap/taz for the treatment of cancer |
| US20220233542A1 (en) * | 2019-06-05 | 2022-07-28 | University Of Georgia Research Foundation | Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension |
| JP7514508B2 (ja) * | 2020-05-19 | 2024-07-11 | 国立大学法人鳥取大学 | 胆道がん治療薬 |
| US20240082158A1 (en) * | 2020-05-21 | 2024-03-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition |
| CN116421591A (zh) * | 2023-05-10 | 2023-07-14 | 哈尔滨医科大学大庆分校 | Ldha抑制剂在制备治疗肺动脉高压的药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5798345A (en) | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
| US5707608A (en) | 1995-08-02 | 1998-01-13 | Qlt Phototherapeutics, Inc. | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
| US5756541A (en) | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US7943179B2 (en) | 2003-09-23 | 2011-05-17 | Massachusetts Institute Of Technology | pH triggerable polymeric particles |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| WO2009102707A2 (en) * | 2008-02-11 | 2009-08-20 | Auspex Pharmaceuticals, Inc. | Substituted oxazaphosphorines |
| WO2009121031A1 (en) * | 2008-03-27 | 2009-10-01 | Vascular Biosciences, Inc. | Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases |
| KR100963435B1 (ko) | 2008-06-19 | 2010-06-17 | 한국과학기술연구원 | 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법 |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP3116872A4 (en) | 2014-03-14 | 2017-08-30 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| WO2015171641A1 (en) | 2014-05-05 | 2015-11-12 | Brigham And Women's Hospital, Inc. | Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases |
| US20160058759A1 (en) * | 2014-07-03 | 2016-03-03 | Board Of Regents, The University Of Texas System | Glutaminase inhibitor therapy |
| US10660861B2 (en) | 2014-07-09 | 2020-05-26 | The Johns Hopkins University | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy |
| EP3693004A1 (en) * | 2014-08-01 | 2020-08-12 | The Brigham and Women's Hospital, Inc. | An inhibitor of gdf-15 for use in treating fibrosis |
| WO2016054388A1 (en) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Glutaminase inhibitors |
| WO2016077632A2 (en) * | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
| WO2016130889A1 (en) | 2015-02-12 | 2016-08-18 | The Johns Hopkins University | Inhibition of yap for breaking tumor immune tolerance |
| EP3316910A4 (en) | 2015-07-02 | 2019-05-01 | Children's Medical Center Corporation | UPPER TRIPLET TRIPLET ANNIHILATION UPWARD IMPLEMENTATION |
| WO2017095751A1 (en) | 2015-12-02 | 2017-06-08 | Partikula Llc | Compositions and methods for modulating cancer cell metabolism |
| US10925869B2 (en) * | 2016-05-26 | 2021-02-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for treating pulmonary vascular disease |
| EP3713569B1 (en) * | 2017-11-22 | 2024-03-13 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Therapeutic particle comprising a yap1/wwrt1 inhibiting agent and the glutaminase inhibiting agent 2-cyclopropyl-n-[5-(4-{ [5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]amino}piperidin-1-yl)-1,3,4-thiadiazol-2-yl] acetamide and use thereof for treating a pulmonary disease |
-
2017
- 2017-05-25 US US16/303,369 patent/US10925869B2/en active Active
- 2017-05-25 EP EP17803564.8A patent/EP3463574B1/en active Active
- 2017-05-25 AU AU2017270092A patent/AU2017270092B2/en active Active
- 2017-05-25 CN CN201780044719.7A patent/CN109843378B/zh active Active
- 2017-05-25 KR KR1020227028385A patent/KR20220120711A/ko not_active Ceased
- 2017-05-25 KR KR1020187037697A patent/KR102434879B1/ko active Active
- 2017-05-25 EP EP21205602.2A patent/EP3970720B1/en active Active
- 2017-05-25 JP JP2018561938A patent/JP7079937B2/ja active Active
- 2017-05-25 WO PCT/US2017/034420 patent/WO2017205595A1/en not_active Ceased
- 2017-05-25 CN CN202210549523.6A patent/CN115192719B/zh active Active
-
2021
- 2021-01-14 US US17/148,701 patent/US11672795B2/en active Active
-
2022
- 2022-05-16 JP JP2022079875A patent/JP7411967B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519533A5 (OSRAM) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| SA521422270B1 (ar) | Apol1 مثبطات لـ وطرق لاستخدامها | |
| JP2014507446A5 (OSRAM) | ||
| JP2019516739A5 (OSRAM) | ||
| JP2016534059A5 (OSRAM) | ||
| JP2015024998A5 (OSRAM) | ||
| JP2015508749A5 (OSRAM) | ||
| CN114555588A (zh) | 作为axl抑制剂的喹唑啉类化合物 | |
| JP2017141277A5 (OSRAM) | ||
| JP2019510081A5 (OSRAM) | ||
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| JP2020502047A5 (OSRAM) | ||
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| JP2019531279A5 (OSRAM) | ||
| MX2018004043A (es) | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. | |
| JP2017530163A5 (OSRAM) | ||
| EP3999121A4 (en) | Treatment/prevention of disease by linc complex inhibition | |
| CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo | |
| JPWO2023195530A5 (OSRAM) | ||
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| JP2017505809A5 (OSRAM) | ||
| JP2016532632A5 (OSRAM) |